25 related articles for article (PubMed ID: 38672219)
1. Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach.
Kim B; Kim G; Kim H; Song YS; Jung J
Cells; 2024 Jan; 13(2):. PubMed ID: 38247807
[TBL] [Abstract][Full Text] [Related]
2. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.
Yang F; He Y; Ge N; Guo J; Yang F; Sun S
Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS-mutant human lung cancer cells.
Peter RM; Sarwar MS; Mostafa SZ; Wang Y; Su X; Kong AN
Mol Carcinog; 2023 Aug; 62(8):1136-1146. PubMed ID: 37144836
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways.
Brandi J; Dando I; Pozza ED; Biondani G; Jenkins R; Elliott V; Park K; Fanelli G; Zolla L; Costello E; Scarpa A; Cecconi D; Palmieri M
J Proteomics; 2017 Jan; 150():310-322. PubMed ID: 27746256
[TBL] [Abstract][Full Text] [Related]
5. Screening Metabolic Biomarkers in
Liu Q; Lan J; Martínez-Jarquín S; Ge W; Zenobi R
Anal Chem; 2024 Mar; 96(12):4918-4924. PubMed ID: 38471062
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic Approach to Identify Potential Biomarkers in KRAS-Mutant Pancreatic Cancer Cells.
Kim B; Jung J
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672219
[TBL] [Abstract][Full Text] [Related]
7. KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer.
Pupo E; Avanzato D; Middonti E; Bussolino F; Lanzetti L
Front Oncol; 2019; 9():848. PubMed ID: 31544066
[TBL] [Abstract][Full Text] [Related]
8. KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism.
Muyinda IJ; Park JG; Jang EJ; Yoo BC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064761
[TBL] [Abstract][Full Text] [Related]
9. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic KRAS signalling in pancreatic cancer.
Eser S; Schnieke A; Schneider G; Saur D
Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884
[TBL] [Abstract][Full Text] [Related]
11. KRAS
Hobbs GA; Der CJ
Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
